Moolec Science MLECW
NASDAQ MLECW
$0.02 +0.00 (+2.56%)
As of: Aug 19, 2026 · 2:06 PM EDT

Moolec Science (MLECW) Non-Current Assets (2022 - 2025)

Moolec Science (MLECW) posted Non-Current Assets of $173.4 million for Q2 2025, up 693.91% sequentially from $21.8 million in Q4 2024, and down 66.12% YoY from $511.6 million in Q2 2024.

Moolec Science (MLECW) Non-Current Assets (2022 - 2025) Analysis & Trends

Moolec Science has reported Non-Current Assets for 4 years, with the latest figure at $173.4 million in Q2 2025.

  • Quarterly Non-Current Assets fell 66.12% year-over-year to $173.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $728.2 million (up 28.2% YoY) and the FY2025 annual result came in at $173.4 million, down 66.12% from the prior year.
  • Non-Current Assets climbed to $173.4 million in Q2 2025 per MLECW's latest filing, from $21.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $511.6 million in Q2 2024 and troughed at -$26.6 million in Q2 2023.
  • A 4-year average of $70.9 million and a median of $19.3 million in 2023 frame the typical range for Non-Current Assets.
  • The sharpest annual moves came in 2023 and 2024: Non-Current Assets slumped 676.23% in 2023, then soared 2026.92% in 2024.
  • Over 4 years, Non-Current Assets stood at $12.7 million in 2022, then soared by 39.45% to $17.8 million in 2023, then rose by 22.88% to $21.8 million in 2024, then jumped by 693.91% to $173.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $173.4 million, $21.8 million, and $21.4 million for Q2 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 5.15 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 1.96 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 938.60 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 6.80 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 468.65 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 18.06 Bn
10 Moolec Science 8,617.72 -1.19 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 173.36 Mn
Dec 31, 2024 21.84 Mn
Sep 30, 2024 21.40 Mn
Jun 30, 2024 511.63 Mn
Mar 31, 2024 19.34 Mn
Dec 31, 2023 17.77 Mn
Sep 30, 2023 19.29 Mn
Jun 30, 2023 -26.55 Mn
Mar 31, 2023 5.01 Mn
Dec 31, 2022 12.74 Mn
Jun 30, 2022 4.61 Mn